The combination of BGB-3111 and obinutuzumab for follicular lymphoma: promising preliminary results
What role will minimal residual disease testing play in multiple myeloma?
Is FISH becoming obsolete in multiple myeloma?
Are IDH mutations good minimal residual disease (MRD) markers in acute myeloid leukemia (AML)?
Increased risk of myeloma in rescue workers exposed to smoke and toxins after 9/11